Biomarkers for Detection and Surveillance of Bladder Cancer

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2008 Aug 7

PMID 18682775

Citations 49

Authors

Lorne I Budman

Wassim Kassouf

Jordan R Steinberg

Affiliations

Soon will be listed here.

Abstract

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary-based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.

Results: SENSITIVITY AND SPECIFICITY RANGES, RESPECTIVELY, FOR EACH MARKER WERE REPORTED AS FOLLOWS: BTA Stat (Polymedco), 52.5%-78.0% and 69.0%-87.1%; BTA Trak (Polymedco), 51%-100% and 73%-92.5%; cytology, 12.1%-84.6% and 78.0%-100%; hematuria dipstick, 47.0%-92.6% and 51.0%-84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%-100% and 60.0%-95.0%; NMP22 BladderChek (Matritech), 49.5%-65.0% and 40.0%-89.8%; ImmunoCyt/uCyt+ (DiagnoCure), 63.3%-84.9% and 62.0%-78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%-89.3% and 61.0%-77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%-100% and 65.0%-96.0%.

Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

Citing Articles

Analysis the diagnostic performance of H4C6/SOX1-OT gene methylation in bladder cancer based on urine sample.

Wang W, Yang X, Li W, Cheng J, Wu J, Cai J Sci Rep. 2025; 15(1):6961.

PMID: 40011626 PMC: 11865265. DOI: 10.1038/s41598-025-91337-w.

Bladder cancer biomarkers: current approaches and future directions.

Ahangar M, Mahjoubi F, Mowla S Front Oncol. 2024; 14:1453278.

PMID: 39678505 PMC: 11638051. DOI: 10.3389/fonc.2024.1453278.

Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.

Angel E Iran J Pathol. 2023; 18(3):257-269.

PMID: 37942190 PMC: 10628378. DOI: 10.30699/IJP.2023.1972203.3004.

Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.

Fiorentino V, Pizzimenti C, Franchina M, Rossi E, Tralongo P, Carlino A Int J Mol Sci. 2023; 24(15).

PMID: 37569864 PMC: 10420163. DOI: 10.3390/ijms241512489.

Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers.

Tyagi H, Daulton E, Bannaga A, Arasaradnam R, Covington J Biosensors (Basel). 2021; 11(11).

PMID: 34821653 PMC: 8615657. DOI: 10.3390/bios11110437.

References

Sarosdy M, Kahn P, Ziffer M, Love W, Barkin J, Abara E . Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006; 176(1):44-7. DOI: 10.1016/S0022-5347(06)00576-3. View

Messing E, Teot L, Korman H, Underhill E, Barker E, Stork B . Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005; 174(4 Pt 1):1238-41. DOI: 10.1097/01.ju.0000173918.84006.4d. View

Krause F, Rauch A, Schrott K, Engehausen D . Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?. World J Urol. 2006; 24(4):418-22. DOI: 10.1007/s00345-006-0086-y. View

Bastacky S, Ibrahim S, Wilczynski S, MURPHY W . The accuracy of urinary cytology in daily practice. Cancer. 1999; 87(3):118-28. DOI: 10.1002/(sici)1097-0142(19990625)87:3<118::aid-cncr4>3.0.co;2-n. View

Fey E, Krochmalnic G, Penman S . The nonchromatin substructures of the nucleus: the ribonucleoprotein (RNP)-containing and RNP-depleted matrices analyzed by sequential fractionation and resinless section electron microscopy. J Cell Biol. 1986; 102(5):1654-65. PMC: 2114208. DOI: 10.1083/jcb.102.5.1654. View

Heney N, Ahmed S, FLANAGAN M, Frable W, Corder M, Hafermann M . Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130(6):1083-6. DOI: 10.1016/s0022-5347(17)51695-x. View

Zellweger T, Benz G, Cathomas G, Mihatsch M, Sulser T, Gasser T . Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006; 119(7):1660-5. DOI: 10.1002/ijc.21704. View

Diamandis E . How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem. 2004; 50(5):793-5. DOI: 10.1373/clinchem.2004.032177. View

Dey P . Urinary markers of bladder carcinoma. Clin Chim Acta. 2004; 340(1-2):57-65. DOI: 10.1016/j.cccn.2003.11.008. View

10.

Gordon J, Shu W, Schlussel R, Droller M, Liu B . Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res. 1993; 53(20):4971-7. View

11.

Halling K, King W, Sokolova I, Karnes R, Meyer R, Powell E . A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002; 167(5):2001-6. View

12.

Boman H, Hedelin H, Jacobsson S, Holmang S . Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol. 2002; 168(5):1955-9. DOI: 10.1016/S0022-5347(05)64271-1. View

13.

Svatek R, Sagalowsky A, Lotan Y . Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol. 2006; 24(4):338-43. DOI: 10.1016/j.urolonc.2005.11.025. View

14.

Khan M, Shaw G, Paris A . Is microscopic haematuria a urological emergency?. BJU Int. 2002; 90(4):355-7. DOI: 10.1046/j.1464-410x.2002.02901.x. View

15.

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View

16.

Tsui K, Chen S, Wang T, Juang H, Chen C, Sun G . Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl. 2007; 9(5):711-5. DOI: 10.1111/j.1745-7262.2007.00218.x. View

17.

Toma M, Friedrich M, Hautmann S, Jakel K, Erbersdobler A, Hellstern A . Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004; 22(2):145-9. DOI: 10.1007/s00345-003-0390-8. View

18.

Tetu B, Tiguert R, Harel F, Fradet Y . ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol. 2004; 18(1):83-9. DOI: 10.1038/modpathol.3800262. View

19.

Friedman K, Fox B . The promising future of proteomics in cancer diagnosis and treatment. Eur J Gastroenterol Hepatol. 2005; 17(7):701-3. DOI: 10.1097/00042737-200507000-00002. View

20.

Celis J, Ostergaard M, Basse B, Celis A, Lauridsen J, Ratz G . Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 1996; 56(20):4782-90. View